Actinogen Medical (ASX: ACW) - Managing Director and CEO, Dr Steven Gourlay
Managing Director and CEO, Dr Steven Gourlay
Source: Actinogen Medical
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Actinogen Medical (ACW) appoints a trial manager for its XanaFX phase-two trial in adolescent boys and young adults with Fragile X Syndrome (FXS)
  • Clinical research organisation Worldwide Clinical Trials will manage the recruitment of participants and conduct and implement the trial
  • Worldwide began operating the XanaFX trial and start-up activities after signing a letter of intent with Actinogen in November 2021 worth $944,724, in advance of negotiating and signing a full work order
  • Today’s deal will see the company paid $13.6 million under a full-service contract that appoints Worldwide to globally manage the XanaFX trial
  • ACW shares steady at 11.5 cents

Actinogen Medical (ACW) has officially appointed a trial manager for its XanaFX phase-two clinical trial treating adolescent boys and young adults with Fragile X Syndrome (FXS).

The company said clinical research organisation Worldwide Clinical Trials will be responsible for managing the recruitment of participants and conducting and implementing the trial.

Worldwide, a global clinical research organisation specialising in neurological, paediatric and rare diseases, had already begun trial start-up activities after signing a letter of intent with Actinogen in November 2021 worth $944,724, in advance of negotiating and signing a full work order (WO).

Today’s WO agreement will see Worldwide paid a further $13.6 million under a full-service contract that appoints it to globally manage the XanaFX trial, with oversight from Actinogen.

The XanaFX study will assess cognition, anxiety, sleep and behavioural problems in male adolescents and young adults possessing the full genetic features associated with FXS.

The randomised, placebo-controlled 12-week trial will involve 75 patients in North America, Great Britain, Australia and New Zealand receiving five milligrams (mg) and 10 mg oral doses of Actinogen’s novel small-molecule drug Xanamem.

“There are currently no treatments approved anywhere in the world for FXS, and the commencement of Actinogen’s key XanaFX trial is another important step in our quest to help make a material difference to the quality of life for people and their families living with FXS,” Actinogen Managing Director and CEO Dr Steven Gourlay said.

The company anticipates trial results in 2023.

ACW shares were steady at 11.5 cents at 3:07 pm AEDT.


ACW by the numbers
More From The Market Herald

" ASX employee tests positive for Covid-19

The ASX says an employee has contracted Covid-19.

" ASIC launches official investigation into ASX market outage

The ASX has confirmed today it is officially under investigation from the Australian Securities and Investments…

" ASX sheds more light on last week’s market tech failure

The Australian Securities Exchange has shed some more light on the nature of last week's market…
ASX (ASX:ASX) - Outgoing Managing Director & CEO, Dominic Stevens

" ASX (ASX:ASX) CEO Dominic Stevens announces retirement

ASX (ASX:ASX) Managing Director and CEO Dominic Stevens has announced his retirement as the company reports…